Shopping Cart

Your shopping cart is currently empty

Pimavanserin tartrate

Name: Pimavanserin tartrate
Brand: TargetMol
SKU: T6946
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T6946Cas No. 706782-28-7

Alias ACP-103

Pimavanserin tartrate is a potent 5-HT 2A receptor inverse agonist used to treat Parkinson's disease-related psychosis, with the most potent inhibitory activity on the NFAT signaling pathway.

Pimavanserin tartrate

Copy Product Info

🥰Excellent

Purity: 99.98%

Catalog No. T6946Alias ACP-103Cas No. 706782-28-7

Pimavanserin tartrate is a potent 5-HT 2A receptor inverse agonist used to treat Parkinson's disease-related psychosis, with the most potent inhibitory activity on the NFAT signaling pathway.

Pack Size	Price	USA Warehouse	Global Warehouse
25 mg	$43	In Stock	In Stock
50 mg	$68	In Stock	In Stock
100 mg	$108	In Stock	In Stock
200 mg	$146	In Stock	In Stock
500 mg	$242	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$29	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.98%

Color:White

Resource Download

COA HNMR HPLC LCMS

Product Introduction

Bioactivity

Description	Pimavanserin tartrate is a potent 5-HT 2A receptor inverse agonist used to treat Parkinson's disease-related psychosis, with the most potent inhibitory activity on the NFAT signaling pathway.
Targets&IC50	5-HT2A:8.7(pIC50)
In vitro	METHODS: The pharmacological effects of PVT on TNBC cells were evaluated at specific time points and different concentration ranges (1.25-20 μM). The short-term effects (24-72 hours) of PVT treatment on the proliferation of two TNBC cell lines, 4T1 and MDA-MB-231, were evaluated using MTT assay. RESULTS The half-maximal inhibitory concentration (IC50) values of PVT on 4T1 cell line at 24 hours, 48 hours and 72 hours were 6.77 μM, 1.94 μM and 1.46 μM, respectively, while the half-maximal inhibitory concentration (IC50) values for MDA-MB-231 were 9.65 μM, 4.24 μM and 2.31 μM, respectively. The inhibitory effect of PVT on the viability of 4T1 and MDA-MB-231 cells showed concentration dependence. However, PVT has a smaller inhibitory effect on the viability of normal human breast epithelial MCF-10A cells.[1]
In vivo	METHODS: Mice were inoculated with 1 × 105 luciferase-expressing 4T1 cells into the left peritoneal cavity. PVT (30 mg/kg) was administered daily by intraperitoneal injection. When the average tumor volume reached approximately 1000 mm3, the tumors were carefully excised and the wounds sutured. To monitor metastasis, a non-invasive in vivo imaging system was used to detect tumor metastasis. The data were collected and analyzed using Living Image® 4.7.2 software. RESULTS PVT mildly inhibited the growth of subcutaneous tumors in vivo without causing significant weight loss in the animals. [1] METHODS: U87 cells were subcutaneously implanted into nude mice to establish a GBM xenograft model. The mice were treated with Pimavanserin tartrate (10 mg/kg, orally, daily, for three weeks), and the tumor growth in the mice was observed. RESULTS Pimavanserin tartrate significantly inhibited tumor growth. [2]
Synonyms	ACP-103

Chemical Properties

Molecular Weight	1005.2
Formula	C₅₀H₆₈F₂N₆O₄·C₄H₆O₆
Cas No.	706782-28-7
Smiles	O[C@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1.CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 93 mg/mL (92.52 mM), Sonication is recommended.

DMSO: 28.05 mg/mL (27.9 mM), Sonication is recommended.

H2O: 92 mg/mL (91.52 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (2.49 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/H2O/Ethanol

	1mg	5mg	10mg	50mg
1 mM	0.9948 mL	4.9741 mL	9.9483 mL	49.7413 mL
5 mM	0.1990 mL	0.9948 mL	1.9897 mL	9.9483 mL
10 mM	0.0995 mL	0.4974 mL	0.9948 mL	4.9741 mL
20 mM	0.0497 mL	0.2487 mL	0.4974 mL	2.4871 mL

H2O/Ethanol

	1mg	5mg	10mg	50mg
50 mM	0.0199 mL	0.0995 mL	0.1990 mL	0.9948 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc